Description
Key facts
Cell type:HEK-293,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 17 bp deletion, 1 bp insertion; Frameshift = 99%
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-E2F1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The E2F1 protein also known as E2F transcription factor 1 is an important regulator of the cell cycle. It has a molecular weight of approximately 47 kDa. E2F1 protein is expressed in many tissues with higher expression levels in proliferating cells. It often acts as a transcription factor by binding to specific DNA sequences controlling the transition of cells from G1 to S phase of the cell cycle. This role is vital for the proper progression of the cycle and cellular proliferation.
Biological function summary
E2F1 plays a significant role in cell growth regulation and apoptosis. E2F1 functions within a complex often forming heterodimers with DP proteins. This combination enhances its ability to bind DNA and activate transcription of genes necessary for DNA replication and cell cycle progression. E2F1 also participates in the control of apoptosis by regulating the expression of pro-apoptotic genes balancing cell proliferation and death.
Pathways
E2F1 is deeply embedded in cell cycle regulatory pathways and the p53 signaling pathway. It closely interacts with proteins like RB (Retinoblastoma protein) and p53. RB protein regulates E2F1 activity by controlling its release while p53 helps in mediating the cell's response to DNA damage potentially leading to either cell cycle arrest or apoptosis. These interactions highlight E2F1's role in maintaining cellular homeostasis.
E2F1 is often linked to cancer and neurodegenerative diseases. Overexpression or dysregulation of E2F1 can lead to uncontrolled cell proliferation contributing to oncogenesis. In the context of neurodegenerative diseases E2F1 influences neuronal apoptosis and may be associated with disorders such as Alzheimer's. E2F1 interacts with other proteins such as p53 in cancer where it affects both cell cycle dynamics and apoptosis illustrating its complex involvement in disease progression.
